← All trials
NCT04756713
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 11, 2021
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2025
- First posted
- Feb 16, 2021
- Last posted
- Feb 16, 2021
- Enrollment
- 150
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Harvard UniversityLead sponsor
- Harvard UniversityReponsible party - principal investigator
- Federal University of Rio de JaneiroStudy director
- Federal University of Rio de JaneiroCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.